Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Oncoimmunology. 2012 Aug 1;1(5):768-769.

    Targeting the tumor mutanome for personalized vaccination therapy.

    Source

    TRON-Translational Oncology at the University Medical Center Mainz; Mainz, Germany.

    Abstract

    Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

    PMID:
    22934277
    [PubMed]
    PMCID:
    PMC3429589
    Free PMC Article

    Images from this publication.See all images (1)Free text

      Supplemental Content

      Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk